Investigation of niclosamide as a repurposing agent for skeletal muscle atrophy
Open Access
- 26 May 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (5) , e0252135
Abstract
Skeletal muscle atrophy is a feature of aging (termed sarcopenia) and various diseases, such as cancer and kidney failure. Effective drug treatment options for muscle atrophy are lacking. The tapeworm medication, niclosamide is being assessed for repurposing to treat numerous diseases, including end-stage cancer metastasis and hepatic steatosis. In this study, we investigated the potential of niclosamide as a repurposing drug for muscle atrophy. In a myotube atrophy model using the glucocorticoid, dexamethasone, niclosamide did not prevent the reduction in myotube diameter or the decreased expression of phosphorylated FOXO3a, which upregulates the ubiquitin-proteasome pathway of muscle catabolism. Treatment of normal myotubes with niclosamide did not activate mTOR, a major regulator of muscle protein synthesis, and increased the expression of atrogin-1, which is induced in catabolic states. Niclosamide treatment also inhibited myogenesis in muscle precursor cells, enhanced the expression of myoblast markersPax7andMyf5, and downregulated the expression of differentiation markersMyoD,MyoGandMyh2. In an animal model of muscle atrophy, niclosamide did not improve muscle mass, grip strength or muscle fiber cross-sectional area. Muscle atrophy is also feature of cancer cachexia. IC50analyses indicated that niclosamide was more cytotoxic for myoblasts than cancer cells. In addition, niclosamide did not suppress the induction ofiNOS, a key mediator of atrophy, in anin vitromodel of cancer cachexia and did not rescue myotube diameter. Overall, these results suggest that niclosamide may not be a suitable repurposing drug for glucocorticoid-induced skeletal muscle atrophy or cancer cachexia. Nevertheless, niclosamide may be employed as a compound to study mechanisms regulating myogenesis and catabolic pathways in skeletal muscle.Keywords
Funding Information
- National Research Foundation of Korea (NRF) funded by the Korean Government (NRF-2020R1A2C2014194 and NRF-2019R1A2C1006331)
- Bio & Medical Technology Development Program of the NRF funded by the Korean government, MSIP (NRF-2020M3A9G3080282)
- Institute for Information and Communications Technology Promotion (2019-0-00567)
This publication has 61 references indexed in Scilit:
- Cellular and molecular mechanisms of muscle atrophyDisease Models & Mechanisms, 2013
- Molecular and cellular mechanisms of skeletal muscle atrophy: an updateJournal of Cachexia, Sarcopenia and Muscle, 2012
- Structure-Activity Analysis of Niclosamide Reveals Potential Role for Cytoplasmic pH in Control of Mammalian Target of Rapamycin Complex 1 (mTORC1) SignalingJournal of Biological Chemistry, 2012
- A Method for the Direct Identification of Differentiating Muscle Cells by a Fluorescent Mitochondrial DyePLOS ONE, 2011
- Antihelminth Compound Niclosamide Downregulates Wnt Signaling and Elicits Antitumor Responses in Tumors with Activating APC MutationsCancer Research, 2011
- Losartan Restores Skeletal Muscle Remodeling and Protects Against Disuse Atrophy in SarcopeniaScience Translational Medicine, 2011
- Optimal management of sarcopeniaClinical Interventions in Aging, 2010
- Sarcopenia: European consensus on definition and diagnosisAge and Ageing, 2010
- Dependence of dexamethasone-induced Akt/FOXO1 signaling, upregulation of MAFbx, and protein catabolism upon the glucocorticoid receptorBiochemical and Biophysical Research Communications, 2009
- NF-κB-Mediated MyoD Decay during Muscle Wasting Requires Nitric Oxide Synthase mRNA Stabilization, HuR Protein, and Nitric Oxide ReleaseMolecular and Cellular Biology, 2005